Profile: Active Biotech AB develops innovative pharmaceuticals that modulate the body's own immune system. We focus on developing pharmaceuticals for medical fields in which the immune system plays a central role. We offer products to treat multiple sclerosis, as well as lung, renal and pancreatic cancer. Our Rhudex™ is a orally available compound for the treatment of rheumatoid arthritis, which is developed as a disease-modifying drug for the treatment of rheumatic diseases and has a distinct competitive advantage in being the first orally available disease-modifying drug that blocks T-cell stimulation. Our Rhudex™ inhibits the underlying disease process & blocks specific CD80 activation of inflammatory T cells, and inhibits the release of cytokines such as TNF.